Table 1 Incidence of EGFR amplification in breast cancer.
TCGA | METABRIC | MSKCC | Caris | |||||
|---|---|---|---|---|---|---|---|---|
Breast Cancer Subtype | Samples # | EGFR Amplification (%) | Samples # | EGFR Amplification (%) | Samples # | EGFR Amplification (%) | Samples # | EGFR Amplification (%) |
All patients | 816 | 14 (1.7%) | 2173 | 52 (2.4%) | 1918 | 23 (1.2%) | 23160 | 1177 (5.1%) |
Histology | ||||||||
IDC | 489 | 10 (2.0%) | 1660 | 48 (2.9%) | 1473 | 21 (1.4%) | 8411 | 434 (5.2%) |
Mixed IDC/ILC | 88 | 0 (0%) | 218 | 2 (0.9%) | 89 | 0 (0%) | nd | nd |
ILC | 127 | 0 (0%) | 172 | 1 (0.6%) | 299 | 0 (0%) | 1311 | 27 (2.1%) |
Other histologies | 112 | 4 (3.6%) | 123 | 1 (0.8%) | 57 | 2 (3.5%) | 13438 | 716 (5.3%) |
ER and HER2 status | ||||||||
ER+ | 600 | 5 (0.8%) | 1617 | 23 (1.4%) | 1512 | 13 (0.9%) | 10802 | 363 (3.4%) |
ER+/HER2− | 326 | 3 (0.9%) | 1398 | 19 (1.4%) | 1357 | 11 (0.8%) | 9887 | 342 (3.5%) |
ER negative | 175 | 8 (4.6%) | 523 | 28 (5.4%) | 327 | 9 (2.8%) | 6312 | 512 (8.1%) |
HER2 positive | 121 | 3 (2.5%) | 247 | 9 (3.6%) | 240 | 3 (1.3%) | 1625 | 73 (4.5%) |
ER+/HER2+ | 89 | 1 (1.1%) | 108 | 1 (0.9%) | 76 | 1 (1.3%) | 916 | 21 (2.3%) |
ER−/HER2+ | 31 | 2 (6.5%) | 139 | 8 (5.8%) | 79 | 1 (1.3%) | 709 | 52 (7.3%) |
TNBC | 90 | 6 (6.7%) | 335 | 19 (5.7%) | 251 | 8 (3.2%) | 5335 | 446 (8.4%) |
Molecular subtype | ||||||||
Total profiled | 587 | 10 (1.7%) | 1980 | 47 (2.4%) | nd | nd | 12872 | 611 (4.6%) |
Luminal A | 307 | 2 (0.7%) | 700 | 5 (0.7%) | nd | nd | 1764 | 51 (2.9%) |
Luminal B | 122 | 2 (1.6%) | 475 | 7 (1.5%) | nd | nd | 5402 | 153 (2.8%) |
HER2 enriched | 51 | 2 (3.9%) | 224 | 12 (5.4%) | nd | nd | 2233 | 173 (7.7%) |
Basal | 107 | 4 (3.7%) | 209 | 17 (8.1) | nd | nd | 3367 | 230 (6.8%) |
Claudin low | nd | nd | 218 | 3 (1.4%) | nd | nd | nd | nd |
Normal | nd | nd | 148 | 3 (2.0%) | nd | nd | 106 | 4 (3.8%) |
